COX-2 siRNA + dextran nanoplex

COX-2 siRNA + dextran nanoplex is an experimental, research-stage RNA interference (RNAi)-based therapeutic designed for the targeted downregulation of cyclooxygenase-2 (COX-2). It consists of small interfering RNA (siRNA) targeting COX-2 complexed with an acid-degradable, cationic dextran nanopolymer carrier. The dextran scaffold is functionalized with amine groups via acid-cleavable acetal bonds, which allow electrostatic condensation with the siRNA. Upon endocytosis into the acidic intracellular environment of tumor cells, these amine groups are rapidly cleaved and released, minimizing the proinflammatory side effects and carrier-induced COX-2 upregulation typically associated with artificial cationic polymers. Downregulation of COX-2 subsequently reduces levels of its major downstream product, prostaglandin E2 (PGE2). Developed by researchers at Johns Hopkins University, this nanoplex has demonstrated effective in vivo tumor accumulation and COX-2 silencing in breast cancer models.

Other names

COX-2 siRNA/dextranCOX-2 siRNA/dextran nanoplexdextran COX-2 siRNA nanoplex